
https://www.science.org/content/blog-post/who-dares-wins
# Who Dares, Wins?
27 Feb 2002

## 1. SUMMARY
This commentary discusses Elan Pharmaceuticals' pioneering vaccine trial for Alzheimer's disease, which targeted beta-amyloid protein deposits in the brain through an immune response approach. The article notes that while attacking one's own proteins with immunotherapy was considered "gutsy," the strategy showed promise after Elan successfully cleared amyloid deposits in genetically engineered rodents. However, the trial encountered severe safety problems, with several patients developing central nervous system inflammation, suggesting the immune response had become uncontrolled. The author expresses disappointment that this setback would delay future attempts at this ambitious therapeutic approach for a disease consuming substantial research resources.

## 2. HISTORY
The article's subject is the AN1792 vaccine trial, which was halted in January 2002 due to aseptic meningoencephalitis in 6% of patients. Subsequent investigation revealed that the trial's adjuvant (QS-21) drove a Th1-mediated inflammatory response that crossed into the brain. While the trial failed therapeutically and safety-wise, it produced crucial data: some patients who mounted anti-amyloid antibody responses showed slower cognitive decline, validating amyloid as a viable target. The amyloid hypothesis dominated Alzheimer's drug development for the next two decades, leading to subsequent passive immunotherapy approaches (avoiding active vaccination) like bapineuzumab and solanezumab, which also largely failed in Phase 3 trials in the 2010s. In 2021, the controversial FDA approval of Biogen's aducanumab raised doubts about the strength of amyloid clearance as a meaningful clinical endpoint. Finally, in 2023, Eisai's lecanemab received full FDA approval (as Leqembi), demonstrating modest but statistically significant cognitive benefitâ€”slowing decline by 27% over 18 months versus placebo. The field has since seen additional progress with donanemab showing similar results, collectively validating immunotherapy against amyloid as a viable therapeutic pathway.

## 3. PREDICTIONS
The article didn't make explicit predictions but implied several expectations:
* **That it would be years before anyone could safely attempt the approach again**: This held true. The field pivoted from active vaccination to passive immunotherapy (monoclonal antibodies) to reduce uncontrolled inflammation. The next vaccine attempts were cautiously designed with modified adjuvants and protein fragments, resuming more than a decade later.
* **That it would require extensive groundwork before attempting again**: This was correct. Researchers spent years studying the T-cell mediated toxicity mechanisms and developing safer vaccine designs (e.g., CAD106, UB-311, and ACI-24) that avoid triggering Th1 inflammatory responses.

## 4. INTEREST
Rating: **8/10**
While centered around a specific trial, this article captures the risks, therapeutic ambition, and safety pitfalls of immunotherapy for neurodegeneration, prefiguring the two-decade struggle to successfully translate amyloid-targeted immunotherapies into clinically meaningful benefits for Alzheimer's patients.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20020227-who-dares-wins.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_